Population pharmacokinetics in phase I drug development: A phase I study of PK1 in patients with solid tumours

British Journal of Cancer

Volumn 81, Issue 1, 1999, Pages 99-107

  Thomson, A H ^a   Vasey, P A ^a   Murray, L S ^a   Cassidy, J ^c   Fraier, D ^b   Frigerio, E ^b   Twelves, C ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b Bioanalytical Laboratory   (Italy)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

PK1 doxorubicin; Population pharmacokinetics; Solid tumours

Indexed keywords

COPOLYMER; DOXORUBICIN;

ADULT; AGED; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HUMAN; KIDNEY FUNCTION; LIVER FUNCTION; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG CARRIERS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; POLYMETHACRYLIC ACIDS;

EID: 0032867961     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690657     Document Type: Article

References (25)

1. Amantea MA, Forrest A, Northfelt DW and Mamelok R (1997) Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma. Clin Pharmacol Ther 61: 301-311
2. Beal SL, Sheiner LB and Boeckmann AJ (1994) NONMEM IV User's Guide, Parts I-VI, NONMEM Project Group, University of California, San Francisco
3. Bronchud MH, Margison JM, Howell A, Lind M, Lucas SB and Wilkinson PM (1990) Comparative pharmacokinetics of escalating doses of doxorubicin in patients with metastatic breast cancer. Cancer Chemother Pharmacol 25: 435-439
4. Bruno R, Vivier N, Vergniol JC, DePhillips SL, Montay G and Sheiner LB (1996) A population pharmacokinetic model for taxotere: model building and validation. J Pharmacokinet Biopharm 24: 153-172
5. Chabot GG, Abigerges D, Calimel G, Culine S, Deforni R, Extra JM, Mahjoubi H, Herait P, Armand JP, Bugat R, Clavel M and Marty ME (1995) Population pharmacokinetics and pharmacodynamics of irinolecan (CPT-11) and active metabolite SN-38 during Phase I trials. Ann Oncol 6: 141-151
6. Chatelut E, Canal P, Brunner V, Chevreau C, Pujol A, Boneu A, Roche H, Houin G and Bugat R (1995) Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 87: 513-580
7. Cockeroft DW and Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16: 31-41
8. Dobbs NA, Twelves CJ, Gillies H, James CA, Harper PG and Rubens RD (1995) Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry. Cancer Chemother Pharmacol 36: 473-476
9. Duncan R, Cable HC, Lloyd JH, Rejmanova P and Kopecek J (1982) Degradation of side chains of N-(2-hydroxypropyl)methacrylamide) copolymers by lysosomal thioproteinases. Bioscience Rep. 2: 1041-1046
10. Fraier D, Frigerio E, Pianezzola E, Strolin Benedetti M, Cassidy J and Vasey P (1995) A sensitive procedure for the quantitation of free and N-(2-hydroxypropyl) methaerylamide polymer-bound doxorubicin (PK 1) and some of its metabolites, 13 dihydrodoxorubicin, 13-dihydrodoxorubicine and doxorubicinone, in human plasma and urine by reversal-phase HPLC with fluorimetric detection. J Pharm Biomed Anal 13: 625-633
11. Jacquet J-M, Bressolle F, Galtier M, Bourrier M, Donadio D, Jourdan J and Rossi J F (1996) Doxorubicin and doxorubicinol: intra-and inter-individual variations of pharmacokinetic parameters. Cancer Chemother Pharmacol 27: 219-225
12. Jodrell DI, Reyno LM, Sridhara R, Eisenberger MA, Tkaezuk KH, Zubowski EG, Sinibaldi VJ, Novak MJ and Egorin MJ (1994) Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer. J Clin Oncol 12: 166-175
13. Launay Iliadis MC, Bruno R, Cosson V, Vergniol JC, Oulidaissa D, Marty M, Clavel M, Aapro M, Lebail N and Iliadis A (1995) Population pharmacokinetics of docetaxel during Phase 1 studies using nonlinear mixed effect modelling and nonparametric maximum likelihood estimation. Cancer Chemother Pharmacol 37: 47-54
14. Maeda H and Matsumura Y (1989) Tumoritropic and lymphotropic principles of macromolecular drugs. CRC Crit Rev Ther Drug Carrier Sys 6: 193-210
15. Matsumura Y and Maeda H (1986) A new concept for macromolecular therapeutics in cancer chemotherapy; mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res 46: 6387-6392
16. McLeod HL, Graham MA, Aamdal S, Setanoians A, Groot Y, Lund B and EORTC Early Clinical Trials Group (1996) Phase I pharmacokinetics and limited sampling strategies for the bioreductive alkylating drug EO9. Eur J Cancer 32A: 1518-1522
17. Nguyen L, Chatelut E, Chevreau C, Tranchand B, Lochon I, Bachaud JM, Pujol A, Hotlin G, Bugat R and Canal P (1998) Population pharmacokinetics of total and unbound etoposide. Cancer Chemother Pharmacol 41: 125-132
18. Piscitelli SC, Rodvold KA, Rushing DA and Tewksbury DA (1993) Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer. Clin Pharmacol Ther 53: 555-561
19. Reyno LM, Egorin MJ, Eisenberger MA, Sinibaldi VJ, Zubowski EG and Sridhara R (1995) J Clin Oncol 13: 2187-2195
20. Samara E and Granneman R (1997) Role of population pharmacokinetics in drug development. A pharmaceutical industry perspective. Clin Pharmacokinet 32: 294-312
21. Schoemaker RC and Cohen AF (1996) Estimating impossible curves using NONMEM. Br J Clin Pharmacol 42: 283-289
22. Telt SE, Holford NHG and McLachlan AJ (1998) Population pharmacokinetics and pharmacodynamics: an underutilised resource. Drug Inf J 32: 693-710
23. Sheiner LB, Rosenberg B and Marathe VV (1977) Estimation of population charactetislics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm 5: 445-479
24. Yuh L, Beal S, Davidian M, Harrison F, Hesler A, Kowalski K, Vonesh E and Wollinger R (1994) Population pharmacokinetic/pharmacodynamic methodology und applications; a bibliography. Biometrics 50: 566-575
25. Vasey PA, Kaye SB, Morrison R, Twelves C, Wilson P, Duncan R, Thomson AH, Murray L, Hilditch TE, Murray T, Burtles S, Fraier D, Frigero E and Cassidy J (1999) Phase I clinical and pharmacokinetic study of PK 1 (HPMA CO-Polymer doxorubicin); first member of a new class of chemotherapeutic agents drug-polymer conjugates. Clin Cancer Res 5: 83-94